8-K: Celularity Secures $1M Loan, Director Departs

Celularity Inc. has entered into a $1 million loan agreement with a trust affiliated with a major shareholder and announced the resignation of a board member.

Summary

• Celularity Inc. has secured a $1,000,000 secured loan from the Philip & Daniele Barach Family Trust, a trust affiliated with a beneficial owner of over five percent of the company's Class A common stock.
• The loan carries an annual interest rate of 4.0%, which can increase to 18.0% upon an event of default.
• The loan matures 30 days after closing or upon the company's receipt of gross proceeds from certain financing or strategic transactions.
• The loan is secured by a first-priority security interest in substantially all of the company's personal property, subject to existing liens.
• As a condition for funding, Robert J. Hariri, M.D. entered into a waiver and subordination agreement regarding indebtedness owed to him by the company.
• Vincent LeVien resigned from the company's Board of Directors, effective June 26, 2026, with no stated disagreement with the company's operations, policies, or practices.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the short-term, high-interest loan secured by most of the company's assets, signaling significant liquidity challenges.

Positives

• Secured a $1 million loan to provide immediate funding.
• The loan agreement was with a trust affiliated with a significant shareholder, indicating continued support.
• The interest rate is initially favorable at 4.0% per annum.
• The resignation of the director was not due to any disagreements, suggesting a smooth transition.

Negatives

• The loan interest rate can escalate significantly to 18.0% upon an event of default.
• The loan has a very short maturity date, either 30 days after closing or upon receipt of other financing, indicating a short-term liquidity need.
• The loan is secured by substantially all of the company's personal property, which could impact future financing options.
• The loan constitutes a related person transaction, which may be subject to scrutiny.

Risks

• Potential for default on the loan, leading to a significant increase in interest rates to 18.0%.
• The short maturity of the loan creates pressure to secure additional financing or strategic transactions quickly.
• The collateralization of substantially all personal property could limit future borrowing capacity.
• Reliance on short-term financing suggests ongoing liquidity challenges.

Future Outlook

The company has entered into a short-term loan agreement that matures either 30 days after closing or upon receipt of gross proceeds from certain financing or other strategic transactions, indicating an immediate need for liquidity and a focus on securing additional capital or strategic partnerships.

Industry Context

StockSavvy.ai notes that securing short-term, high-interest debt, especially from related parties, is often a sign of financial distress or an urgent need for capital in the biotechnology sector, which is known for its capital-intensive research and development cycles.

Management Changes

Related Party Transactions

• A $1,000,000 secured loan was entered into with the Philip & Daniele Barach Family Trust, a trust affiliated with Philip Barach, who beneficially owns more than five percent of the Company's outstanding Class A common stock.

Stakeholder Impact

• Shareholders: The short-term nature of the loan and its collateralization may indicate financial distress, potentially impacting share value. The need for rapid financing could lead to dilutive equity offerings.
• Creditors: Existing creditors may face increased risk due to the first-priority security interest granted to the loan provider over substantially all personal property.
• Management: Faces pressure to quickly secure additional funding or strategic transactions to meet the loan's maturity deadline.

Next Steps

• Secure additional financing or complete strategic transactions to repay the $1 million loan within 30 days of closing.
• Manage personal property assets subject to the first-priority security interest.

Key Dates

Recommendation

The company has secured essential short-term funding, but the terms of the loan (high default interest, short maturity, broad collateral) indicate significant financial pressure. While the immediate liquidity is addressed, the underlying need for substantial capital raises remains a concern. Investors should hold and await further clarity on the company's ability to secure longer-term financing or execute strategic transactions before considering a buy or sell decision.

Keywords

Celularity Inc., 8-K, Loan Agreement, Secured Loan, Related Party Transaction, Philip & Daniele Barach Family Trust, Director Resignation, Financing, Liquidity, Nasdaq:CELU, Nasdaq:CELUW